JP2017531613A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531613A5
JP2017531613A5 JP2017500335A JP2017500335A JP2017531613A5 JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5 JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polypeptide
subject
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017500335A
Other languages
English (en)
Japanese (ja)
Other versions
JP6680758B2 (ja
JP2017531613A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/053700 external-priority patent/WO2016054494A1/en
Publication of JP2017531613A publication Critical patent/JP2017531613A/ja
Publication of JP2017531613A5 publication Critical patent/JP2017531613A5/ja
Application granted granted Critical
Publication of JP6680758B2 publication Critical patent/JP6680758B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017500335A 2014-10-03 2015-10-02 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 Expired - Fee Related JP6680758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059682P 2014-10-03 2014-10-03
US62/059,682 2014-10-03
PCT/US2015/053700 WO2016054494A1 (en) 2014-10-03 2015-10-02 Methods and compositions for treatment of conditions associated with elevated triglycerides

Publications (3)

Publication Number Publication Date
JP2017531613A JP2017531613A (ja) 2017-10-26
JP2017531613A5 true JP2017531613A5 (cg-RX-API-DMAC7.html) 2018-11-08
JP6680758B2 JP6680758B2 (ja) 2020-04-15

Family

ID=55631597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017500335A Expired - Fee Related JP6680758B2 (ja) 2014-10-03 2015-10-02 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物

Country Status (7)

Country Link
US (3) US10071139B2 (cg-RX-API-DMAC7.html)
EP (2) EP3201225B1 (cg-RX-API-DMAC7.html)
JP (1) JP6680758B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015327900B2 (cg-RX-API-DMAC7.html)
CA (1) CA2954082A1 (cg-RX-API-DMAC7.html)
ES (1) ES2819866T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016054494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6680758B2 (ja) 2014-10-03 2020-04-15 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
SG11201806176PA (en) * 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Angptl3阻害剤と組み合わせてpcsk9阻害剤を投与することにより高脂血症を有する患者を処置するための方法
US20190177391A1 (en) * 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
ES2896107T3 (es) * 2016-04-08 2022-02-23 Regeneron Pharma Métodos para tratar la hiperlipidemia con un inhibidor de ANGPTL8 y un inhibidor de ANGPTL3
EP3541839A1 (en) 2016-11-17 2019-09-25 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
CA3080148A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
AU2012267492A1 (en) 2011-06-10 2014-01-09 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
US9644021B2 (en) * 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
EP4269421A3 (en) 2013-10-11 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
JP6680758B2 (ja) 2014-10-03 2020-04-15 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
EP3541839A1 (en) 2016-11-17 2019-09-25 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
CA3080148A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2017531613A5 (cg-RX-API-DMAC7.html)
JP7474729B2 (ja) 肺高血圧症を治療するための組成物および方法
US12122819B2 (en) Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant
JP2014526441A5 (cg-RX-API-DMAC7.html)
JP2014521684A5 (cg-RX-API-DMAC7.html)
Chrysant et al. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors
JP2019178132A5 (cg-RX-API-DMAC7.html)
US10702587B2 (en) Angiopoietin-like protein 8 polypeptide fragments and compositions thereof
JP2024010052A (ja) 組織石灰化の治療方法
JP2016511752A5 (cg-RX-API-DMAC7.html)
JP2012509902A5 (cg-RX-API-DMAC7.html)
JP2016512213A5 (cg-RX-API-DMAC7.html)
AU2020340618B2 (en) Therapeutic fusion proteins
JP2016516016A5 (cg-RX-API-DMAC7.html)
JP2016536357A5 (cg-RX-API-DMAC7.html)
JP2009510999A (ja) キメラ治療剤
JP2019514908A5 (cg-RX-API-DMAC7.html)
JP2014519514A5 (cg-RX-API-DMAC7.html)
CA3022152A1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
WO2013103972A1 (en) Treatment of frailty syndrome and symptoms thereof
CN102120755B (zh) 一种棕色脂肪组织靶向性多肽及其应用
JP2007515157A5 (cg-RX-API-DMAC7.html)
WO2018019840A1 (en) Pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome
JP2017509602A5 (cg-RX-API-DMAC7.html)
Yoo Infliximab/mesalazine